Daewoong Pharmaceutical Targets Global Market with ‘Obesity Patch’
Daewoong Pharmaceutical has signed a global licensing deal for microneedle-based obesity patches, aiming to capture a share of the rapidly expanding $200 billion global obesity treatment market by 2030.
Daewoong Pharmaceutical is making a major investment in smart manufacturing infrastructure and seeking synergy with South Korea’s National Growth Fund to boost global competitiveness in the pharmaceutical and biotech sectors.
#YonhapInfomax #DaewoongPharmaceutical #NationalGrowthFund #SmartFactory #RDInvestment #GlobalCompetitiveness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=105355
Daewoong Pharmaceutical Announces Major Investment in Smart Manufacturing Infrastructure—Seeks Synergy with National Growth Fund
Daewoong Pharmaceutical is making a major investment in smart manufacturing infrastructure and seeking synergy with South Korea’s National Growth Fund to boost global competitiveness in the pharmaceutical and biotech sectors.
Daewoong Pharmaceutical Reports Q4 Operating Profit of 45.5 Billion Won, Up 8.97% Year-on-Year
Daewoong Pharmaceutical Co. posted an 8.97% year-on-year rise in Q4 operating profit to 45.5 billion won, with revenue and net profit also showing solid growth.
Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ExportDeal #MexicoMarket #BotulinumToxin #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=102961
Daewoong Pharmaceutical Exports Nabota to Mexico in 29.5 Billion Won Deal
Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.
Daewoong Pharmaceutical Vice Chairman Yoon Jae-chun Says 'Lack of Funds Prevents Global Clinical Trials—Industry Cannot Withstand Drug Price Cuts'
Daewoong Pharmaceutical's Vice Chairman warns that South Korea's drugmakers lack funds for global R&D and cannot withstand the government's planned drug price cuts, highlighting industry-wide financial strain.
Daewoong Pharmaceutical Initiates Liquidation Process for US Stem Cell Partner with 20% Stake
Daewoong Pharmaceutical announced that its US stem cell partner Immplacate, in which it holds a 20% stake, has entered liquidation, raising questions about investment recovery.
Daewoong Pharmaceutical Unveils V-OLET Clinical Cases for the First Time in China
Daewoong Pharmaceutical showcased its fat-dissolving injectable V-OLET and unveiled clinical data for the first time in China at AMWC CHINA 2025, aiming to expand its global medical aesthetics presence.
Daewoong Pharmaceutical has signed a 33.7 billion won export deal for its diabetes drug Enblo in eight Latin American countries, expanding its global footprint and accelerating portfolio diversification.
#YonhapInfomax #DaewoongPharmaceutical #Enblo #ExportDeal #LatinAmerica #DiabetesMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=90787
Daewoong Pharmaceutical Posts 30.1% Rise in Q3 Operating Profit to 53.5 Billion Won
Daewoong Pharmaceutical reported a robust 30.1% year-on-year increase in third-quarter operating profit, reaching 53.5 billion won, signaling strong earnings momentum.
Yonhap Infomax News